Menu

GlaxoSmithKline

GSK announces new data from phase III studies of sirukumab in adult patients with moderately to severely active rheumatoid arthritis

, , ,

London – 16 November 2016 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced results from two pivotal phase III studies evaluating subcutaneous sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody in development for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). The first study (SIRROUND-T), in patients who were refractory to or intolerant to […]

GSK completes divestment of rights to ofatumumab for auto-immune indications to Novartis

, , , ,

21 December 2015, London – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the completion of its transaction to divest its rights to ofatumumab for auto-immune indications to Novartis Pharma AG (“Novartis Pharma”), a subsidiary of Novartis AG, following regulatory approval. The consideration payable by Novartis Pharma to GSK may reach up to $1,034 million and comprises a series […]

GSK’s global HIV business ViiV Healthcare to acquire Bristol-Myers Squibb’s R&D HIV assets

, , , , ,

Two transactions further strengthen HIV pipeline and outlook 18 December 2015, London – GlaxoSmithKline plc (LSE: GSK) today announced that its global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb, to acquire its late-stage HIV R&D assets; and to acquire Bristol-Myers Squibb’s portfolio of preclinical and discovery stage HIV research assets. Under the […]

1 2